Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

Although the prevalence of diabetes-related eye diseases almost doubled since 2014, the rates of most severe forms of the disease have actually decreased, according to a new study led by researchers ...